Cargando…
Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
Effective therapeutic strategies for triple-negative breast cancer (TNBC) are still lacking. Clinical data suggest that a large number of TNBC patients cannot benefit from single immune checkpoint inhibitor (ICI) treatment due to the immunosuppressive tumour microenvironment (TME). Therefore, combin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113929/ https://www.ncbi.nlm.nih.gov/pubmed/34561555 http://dx.doi.org/10.1038/s41417-021-00389-3 |
_version_ | 1784709670704775168 |
---|---|
author | Zhang, Huan Xie, Weimin Zhang, Yuning Dong, Xiwen Liu, Chao Yi, Jing Zhang, Shun Wen, Chunkai Zheng, Li Wang, Hua |
author_facet | Zhang, Huan Xie, Weimin Zhang, Yuning Dong, Xiwen Liu, Chao Yi, Jing Zhang, Shun Wen, Chunkai Zheng, Li Wang, Hua |
author_sort | Zhang, Huan |
collection | PubMed |
description | Effective therapeutic strategies for triple-negative breast cancer (TNBC) are still lacking. Clinical data suggest that a large number of TNBC patients cannot benefit from single immune checkpoint inhibitor (ICI) treatment due to the immunosuppressive tumour microenvironment (TME). Therefore, combination immunotherapy is an alternative approach to overcome this limitation. In this article, we combined two kinds of oncolytic adenoviruses with ICIs to treat TNBC in an orthotopic mouse model. Histopathological analysis and immunohistochemistry as well as multiplex immunofluorescence were used to analyse the TME. The immunophenotype of the peripheral blood and spleen was detected by using flow cytometry. Oncolytic adenovirus-mediated immune activity in a coculture system of lytic supernatant and splenocytes supported the study of the mechanism of combination therapy in vitro. Our results showed that the combination of oncolytic adenoviruses with anti-programmed cell death-ligand 1 (anti-PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (anti-CTLA-4) (aPC) can significantly inhibit tumour growth and prolong survival in a TNBC model. The combination therapy synergistically enhanced the antitumour effect by recruiting CD8(+) T and T memory cells, reducing the number of regulatory T cells and tumour-associated macrophages, and promoting the polarization of macrophages from the M2 to the M1 phenotype to regulate the TME. The rAd.GM regimen performed better than the rAd.Null treatment. Furthermore, aPC efficiently blocked oncolytic virus-induced upregulation of PD-L1 and CTLA-4. These findings indicate that oncolytic adenoviruses can reprogramme the immunosuppressive TME, while ICIs can prevent immune escape after oncolytic virus therapy by reducing the expression of immune checkpoint molecules. Our results provide a mutually reinforcing strategy for clinical combination immunotherapy. |
format | Online Article Text |
id | pubmed-9113929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91139292022-05-19 Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model Zhang, Huan Xie, Weimin Zhang, Yuning Dong, Xiwen Liu, Chao Yi, Jing Zhang, Shun Wen, Chunkai Zheng, Li Wang, Hua Cancer Gene Ther Article Effective therapeutic strategies for triple-negative breast cancer (TNBC) are still lacking. Clinical data suggest that a large number of TNBC patients cannot benefit from single immune checkpoint inhibitor (ICI) treatment due to the immunosuppressive tumour microenvironment (TME). Therefore, combination immunotherapy is an alternative approach to overcome this limitation. In this article, we combined two kinds of oncolytic adenoviruses with ICIs to treat TNBC in an orthotopic mouse model. Histopathological analysis and immunohistochemistry as well as multiplex immunofluorescence were used to analyse the TME. The immunophenotype of the peripheral blood and spleen was detected by using flow cytometry. Oncolytic adenovirus-mediated immune activity in a coculture system of lytic supernatant and splenocytes supported the study of the mechanism of combination therapy in vitro. Our results showed that the combination of oncolytic adenoviruses with anti-programmed cell death-ligand 1 (anti-PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (anti-CTLA-4) (aPC) can significantly inhibit tumour growth and prolong survival in a TNBC model. The combination therapy synergistically enhanced the antitumour effect by recruiting CD8(+) T and T memory cells, reducing the number of regulatory T cells and tumour-associated macrophages, and promoting the polarization of macrophages from the M2 to the M1 phenotype to regulate the TME. The rAd.GM regimen performed better than the rAd.Null treatment. Furthermore, aPC efficiently blocked oncolytic virus-induced upregulation of PD-L1 and CTLA-4. These findings indicate that oncolytic adenoviruses can reprogramme the immunosuppressive TME, while ICIs can prevent immune escape after oncolytic virus therapy by reducing the expression of immune checkpoint molecules. Our results provide a mutually reinforcing strategy for clinical combination immunotherapy. Nature Publishing Group US 2021-09-24 2022 /pmc/articles/PMC9113929/ /pubmed/34561555 http://dx.doi.org/10.1038/s41417-021-00389-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Huan Xie, Weimin Zhang, Yuning Dong, Xiwen Liu, Chao Yi, Jing Zhang, Shun Wen, Chunkai Zheng, Li Wang, Hua Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title | Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title_full | Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title_fullStr | Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title_full_unstemmed | Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title_short | Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model |
title_sort | oncolytic adenoviruses synergistically enhance anti-pd-l1 and anti-ctla-4 immunotherapy by modulating the tumour microenvironment in a 4t1 orthotopic mouse model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113929/ https://www.ncbi.nlm.nih.gov/pubmed/34561555 http://dx.doi.org/10.1038/s41417-021-00389-3 |
work_keys_str_mv | AT zhanghuan oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT xieweimin oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT zhangyuning oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT dongxiwen oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT liuchao oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT yijing oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT zhangshun oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT wenchunkai oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT zhengli oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel AT wanghua oncolyticadenovirusessynergisticallyenhanceantipdl1andantictla4immunotherapybymodulatingthetumourmicroenvironmentina4t1orthotopicmousemodel |